The U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee (insulin glargine-yfgn) as the first generic insulin
Too many people with diabetes are still unaware of modern diabetes measurement tools, such as time in range. We want to change that.
Erin Black of CNBC and also a type 1 diabetic herself, speaks to physicians and others in the diabetes community why people with diabetes are a higher risk of complications if they become infected with Covid 19.
IRVINE, Calif. - March 4, 2020 - The halls of the Visalia Convention Center were buzzing recently with news of a new type of diabetes. Everyone attending the first day of the California Lions Clubs State Convention was curious. Lions Clubs members from across the state were intrigued by this new — and unheard of — type of diabetes. Several physicians attending the convention were puzzled when they were asked, "What is type 3 diabetes?
Then, Lions, physicians and others in healthcare assembled in the San Joaquin conference room, where Brian Ballard was scheduled to speak about the psychology of diabetes. Click here to read more
FRIDAY, Jan. 17, 2020 (HealthDay News) -- From 2001 to 2016, mortality declined among people with diabetes in Hong Kong, according to a study published online Jan. 16 in Diabetologia.
Hongjiang Wu, M.P.H., Ph.D., from the Chinese University of Hong Kong Prince of Wales Hospital, click here to read more
Oak Brook, Illinois, September 6, 2019 – Lions Clubs International and the American Association of Diabetes Educators (AADE) recently signed a Memorandum of Understanding (MOU) to establish a cooperative alliance in the fight against type 2 diabetes. The two organizations will join together to help prevent or delay type 2 diabetes and improve the quality of life for those living with diabetes within the U.S.
Diabetes affects 425 million Read More
San Francisco, California, June 12, 2019 - This year's American Diabetes Association Scientific Sessions held in San Francisco definitely had more of an energetic buzz and air of anticipation than the past few years, if you ask us.
This is most certainly due to the incredible progress in new Artificial Pancreas (aka Closed Loop or Automated Insulin Delivery) systems coming soon, along with better CGM sensors, infusion devices and apps. Not to mention new smart insulin click here to read more